IQV — IQVIA Holdings Inc.

IQVIA Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $4.34 billion, up 10.3% year-over-year (8.1% at constant currency).
• Full Year Revenue: $16.31 billion, up 5.9% reported and 4.8% at constant currency.
• Adjusted Diluted EPS: $3.42 for Q4, up 9.6% year-over-year; full year adjusted EPS at $11.92, up 7.1%.
• Adjusted EBITDA: Q4 at $1.046 billion (5% growth), full year at $3.788 billion (2.8% growth).
• Free Cash Flow: $2.51 billion for the full year, representing 99% of adjusted net income.
• Net Bookings: Over $2.7 billion in Q4, with a book-to-bill ratio of 1.18.
• Backlog: Reached a record $32.7 billion, up 5.3% year-over-year.

2. Strategic Updates and Business Highlights

• Acquisitions: Notable acquisitions include a facility in the U.K. for Phase I trials and Cedar Gate for payer analytics.
• Partnerships: Collaboration with Amazon Web Services to enhance digital transformation in life sciences.
• AI Initiatives: Continued investment in AI capabilities, with over 150 AI agents deployed across various use cases.
• New Segment Reporting: Transition to two reporting segments (Commercial Solutions and R&D) to align with market evolution.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $17.159 billion and $17.359 billion, including contributions from M&A and foreign exchange.
• Adjusted EBITDA Guidance: Projected between $3.975 billion and $4.25 billion.
• Adjusted Diluted EPS Guidance: Anticipated between $12.55 and $12.85.
• Q1 2026 Guidance: Revenue expected between $4.50 billion and $4.15 billion; adjusted EBITDA between $920 million and $940 million.

4. Bad News, Challenges, or Points of Concern

• Market Conditions: The macroeconomic environment has led to slower customer decision-making and tempered biotech funding, impacting R&D bookings earlier in the year.
• Trial Cancellations: Slightly above normal range of trial cancellations due to specific issues, though overall demand indicators remain positive.
• Margin Pressure: Q4 margins were impacted by high pass-through growth, with expectations for moderation in 2026.

5. Notable Q&A Insights

• AI Disruption Concerns: CEO Ari Bousbib emphasized that AI is an opportunity rather than a threat, asserting that IQVIA's proprietary data and domain expertise make it resilient to disruption.
• Cedar Gate Acquisition: Bousbib highlighted Cedar Gate's role in enhancing payer analytics and improving patient outcomes, with projected revenue of $125 million in 2024.
• Large Pharma Dynamics: There is no significant change in demand dynamics from large pharma clients despite their AI initiatives; rather, these efforts are seen as complementary to IQVIA's services.
• Productivity Gains: While productivity improvements are expected, the company will continue to share these gains with clients, maintaining a balance between pricing pressures and service value.

This summary encapsulates the key financial metrics, strategic initiatives, guidance, challenges, and insights from the Q&A, providing a comprehensive overview of IQVIA's performance and outlook.